EUVIMEDOntdek EUVIMED
Systematische ÜbersichtOpen access · CC BY 4.0

MRI prognostic features in rectal cancer neoadjuvant trials: A systematic review of reporting gaps across two decades

Nikhil Lal iD, Kenneth Jordan Ng Cheong Chung, Nicola Hodges iD, John T Jenkins iD, Gina Brown iD, MERCURY 3 Study Group

Colorectal Disease · 2026-05 · 28 (5)

DOI: 10.1111/codi.70491 ↗

At a glance

Systematische Übersicht in Colorectal Disease, published online on 2026-05-22. Written by Nikhil Lal and 5 co-authors. Institution: Department of Surgery & Cancer, Imperial College London, London, UK. Major MEDLINE topics: Rectal Neoplasms, Neoadjuvant Therapy, Magnetic Resonance Imaging. Cited 1 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Background

Magnetic resonance imaging (MRI) is central to staging and treatment planning in rectal cancer, particularly in identifying candidates for neoadjuvant therapy. Prognostic MRI features such as tumour depth (mrT), extramural venous invasion (EMVI) and tumour deposits (TDs) are increasingly recognised as markers of systemic risk, yet their reporting in randomised controlled trials (RCTs) remains unclear. This systematic review aimed to evaluate the reporting frequency, consistency and integration of pre‐treatment MRI prognostic variables in RCTs assessing neoadjuvant treatment for rectal cancer.

Methods

A systematic search was conducted across MEDLINE, EMBASE, Web of Science and CENTRAL from 01 January 2005 to 18 November 2025. RCTs evaluating neoadjuvant strategies in adult patients with resectable rectal cancer were included. Two reviewers independently extracted data on MRI variables, protocol details and trial design. PRISMA guidelines were followed.

Results

Of 1,283 screened studies, 34 RCTs met inclusion criteria. All studies reported mrT, and 33 (97%) included nodal staging (mrN). mrEMVI was reported in only 10 trials (29.4%), and mrT substage was reported in 5 studies (14.7%). MRI protocols were inconsistently described, with only 5 trials specifying acquisition parameters. Only 10 studies incorporated EMVI into risk stratification frameworks. Four trials did not mandate MRI for baseline staging.

Conclusion

Despite MRI's critical role in rectal cancer management, key prognostic features such as EMVI/TDs and mrT substage are underreported. This omission risks poor risk stratification, trial imbalance and misinformed clinical guidance. Standardisation of MRI reporting is urgently needed to enhance trial validity and optimise personalised treatment strategies.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyMagnetic Resonance ImagingHumansPrognosisRandomized Controlled Trials as TopicNeoplasm StagingNeoplasm Invasiveness

Author keywords

MRIextramural venous invasionrectal cancertumour deposit

Authors and institutions

  • Department of Surgery & Cancer, Imperial College London, London, UK.
  • Complex Cancer Clinic, St Mark's the National Bowel Hospital, London, UK.
  • Imperial College Healthcare NHS Trust, London, UK.
  • Department of Surgery and Cancer, Hammersmith Hospital, London, UK.

ORCID profiles: Nikhil Lal, Nicola Hodges, John T Jenkins, Gina Brown

Funding

  • National Institute for Health and Care Research

Cite

APA

Lal, N., Cheong Chung, K. J. N., Hodges, N., Jenkins, J. T., Brown, G., & MERCURY 3 Study Group (2026). MRI prognostic features in rectal cancer neoadjuvant trials: A systematic review of reporting gaps across two decades. Colorectal Disease, 28(5). https://doi.org/10.1111/codi.70491

Vancouver

Lal N, Cheong Chung KJN, Hodges N, Jenkins JT, Brown G, MERCURY 3 Study Group. MRI prognostic features in rectal cancer neoadjuvant trials: A systematic review of reporting gaps across two decades. Colorectal Disease. 2026;28(5). doi:10.1111/codi.70491

BibTeX
@article{Lal2026,
  author = {Lal, Nikhil and Cheong Chung, Kenneth Jordan Ng and Hodges, Nicola and Jenkins, John T and Brown, Gina and MERCURY 3 Study Group, MERCURY 3 Study Group},
  title = {MRI prognostic features in rectal cancer neoadjuvant trials: A systematic review of reporting gaps across two decades},
  journal = {Colorectal Disease},
  year = {2026},
  volume = {28},
  number = {5},
  doi = {10.1111/codi.70491}
}
Start for free →